Emerging Technologies in the Scale-Up of Therapeutic TIDES Modalities

Abstract

Therapeutic peptides and oligonucleotides (collectively referred to as TIDES) were initially developed to treat rare and orphan diseases, where they addressed critical unmet needs and established the clinical promise of these modalities. In recent years, their impact has grown dramatically, extending to much larger patient populations—for example, therapeutic peptides are now frontline treatments in type 2 diabetes and chronic weight management. This rapid expansion brings with it new challenges in manufacturing, demanding advances in efficiency, cost-effectiveness, and sustainability.

This presentation will highlight Eli Lilly’s efforts to meet these challenges through innovative applications of sustainable chemistry and engineering. I will also provide an overview of Lilly’s Synthetic Molecule

Design and Development (SMDD) Process Chemistry group, emphasizinghow collaboration across disciplines is unlocking new solutions. For students and researchers, the story of TIDES is not only about molecules, but also about the opportunities to shape the future of medicine by connecting fundamental science with large-scale impact.

Biography: 

Eli Lilly and Company, Associate Vice President, Synthetic Molecule Design & Development